Dry-eye treatment shows promising Phase II results

Article

SARcode's lead investigational molecule, SAR 1118, demonstrated promising results in a Phase II study of dry eye disease, according to data presented at this year's Association for Research in Vision and Ophthalmology (ARVO) meeting

SARcode's lead investigational molecule, SAR 1118, demonstrated promising results in a Phase II study of dry eye disease, according to data presented at this year's Association for Research in Vision and Ophthalmology (ARVO) meeting.

The small molecule integrin antagonist inhibits T-cell medicated inflammation and can also be used to treat diabetic macular oedema.

Dr Charles Semba et al., SARcode Corporation, Brisbane, California, USA, conducted a randomized, placebo-controlled, multi centre study on 230 patients with dry eye disease. The Ocular Surface Disease Index (OSDI) was used to evaluate visual-related function. SAR 1118, the potent novel small molecule lymphocyte function-associated antigen, was topically administered to all patients.

It was concluded that SAR 1118 was safe and well tolerated amongst dry eye patients. There were no serious ocular effects recorded, most of them being transient and not related to the administration of SAR 1118. Corneal staining was reduced over 12 weeks, tear production increased after 2 weeks and visual-related functions vastly improved.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.